US Wrap: Barclays returns to reverse convertibles

Barclays has gone reverse convertible crazy in the latest US issuance and the underlyings are hugely varied.

The Reverse Convertible Notes linked to Eldorado Gold issued by the bank have a high riskmap rating of 7.7, partly due to the volatility of the underlying. The six-month investment offers 9% annual returns. There is a 75% barrier, after which capital is lost at the rate of 1:1.

At the other end of the spectrum, the Barclays Reverse Convertible Notes linked to Vertex Pharmaceuticals have a

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact [email protected] or view our subscription options here: http://subscriptions.risk.net/subscribe

You are currently unable to copy this content. Please contact [email protected] to find out more.

To continue reading...

You need to sign in to use this feature. If you don’t have a Risk.net account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here: